Review
Version 1
Preserved in Portico This version is not peer-reviewed
Licensed Anti-Microbial Drugs Logical for Clinical Trials Against Pathogens Currently Suspected in Alzheimer's Disease
Version 1
: Received: 28 January 2021 / Approved: 29 January 2021 / Online: 29 January 2021 (13:57:18 CET)
A peer-reviewed article of this Preprint also exists.
Norins, L.C. Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease. Antibiotics 2021, 10, 327. Norins, L.C. Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease. Antibiotics 2021, 10, 327.
Abstract
There is now considerable evidence that several infectious agents (viruses, bacteria, or parasites) may play a contributing role in the development of Alzheimer’s disease (AD). The six primary suspects are herpes viruses, spirochetal bacteria, Chlamydia pneumoniae, Porphyromonas gingivalis, mycobacteria, and toxoplasma parasites. Also, some of the antimicrobial and antiviral agents that are used to treat them have shown promise for AD interventions. I describe this evidence and assert it is now time to accelerate clinical trials of these existing drugs, already federally approved, to determine if such treatments can delay, halt, or reverse AD.
Keywords
Alzheimer’s disease; dementia, beta-amyloid; germ theory; drug development; clinical trials; herpes; spirochetes; Chlamydia pneumoniae; Porphyromonas gingivalis; toxoplasma; mycobacteria
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment